Details for Patent: 9,062,047
✉ Email this page to a colleague
Which drugs does patent 9,062,047 protect, and when does it expire?
Patent 9,062,047 protects OHTUVAYRE and is included in one NDA.
This patent has twenty-six patent family members in twenty countries.
Summary for Patent: 9,062,047
| Title: | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
| Abstract: | The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern. |
| Inventor(s): | Walker Michael J. A., Plouvier Bertrand M. C., Northen Julian S., Fernandes Philippe |
| Assignee: | Verona Pharma plc |
| Application Number: | US13814877 |
|
Patent Claim Types: see list of patent claims |
Recent additions to Drugs Protected by US Patent 9,062,047
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verona Pharma | OHTUVAYRE | ensifentrine | SUSPENSION | 217389 | Jun 26, 2024 | RX | Yes | ⤷ Sign Up | Y | ⤷ Sign Up | U-3962 | FOR THE MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULT PATIENTS | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 9,062,047
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verona Pharma | OHTUVAYRE | ensifentrine | SUSPENSION;INHALATION | 217389-001 | Jun 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULT PATIENTS | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,062,047
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 082601 | ⤷ Sign Up | |||
| Australia | 2011288497 | ⤷ Sign Up | |||
| Brazil | 112013003087 | ⤷ Sign Up | |||
| Canada | 2807082 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
